pramipexole has been researched along with Anxiety in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (37.50) | 29.6817 |
| 2010's | 5 (62.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chiu, WH; Depboylu, C; Hermanns, G; Höglinger, GU; Maurer, L; Oertel, WH; Ries, V; Windolph, A | 1 |
| Darvas, M; Gibbs, JT; Keene, CD; Melief, EJ; Montine, TJ; Morgan, RG; Palmiter, RD; Postupna, NO; Sherfield, EE; Wilson, A | 1 |
| Boulet, S; Carcenac, C; Carnicella, S; David, O; Krack, P; Magnard, R; Savasta, M; Vachez, Y | 1 |
| Iakhno, NN; Nodel', MR | 1 |
| Nibuya, M; Nomura, S; Takahashi, T | 1 |
| Jimenez-Gomez, C; Osentoski, A; Woods, JH | 1 |
| Chigir', IP; Fedorova, NV | 2 |
1 review(s) available for pramipexole and Anxiety
| Article | Year |
|---|---|
What can rodent models tell us about apathy and associated neuropsychiatric symptoms in Parkinson's disease?
Topics: Anhedonia; Animals; Anxiety; Apathy; Behavior, Animal; Benzothiazoles; Depression; Disease Models, Animal; Dopamine Agonists; Mice; Neostriatum; Parkinson Disease; Pramipexole; Rats; Receptors, Dopamine D2; Receptors, Dopamine D3; Substantia Nigra | 2016 |
1 trial(s) available for pramipexole and Anxiety
| Article | Year |
|---|---|
Use of the dopamine receptor agonist Mirapex in the treatment of Parkinson's disease.
Topics: Activities of Daily Living; Aged; Anxiety; Benzothiazoles; Depression; Dopamine Agonists; Female; Humans; Male; Middle Aged; Parkinson Disease; Pramipexole; Review Literature as Topic; Time Factors | 2007 |
6 other study(ies) available for pramipexole and Anxiety
| Article | Year |
|---|---|
Long-term treatment with L-DOPA or pramipexole affects adult neurogenesis and corresponding non-motor behavior in a mouse model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Anxiety; Benzothiazoles; Depression; Hippocampus; Levodopa; Male; Mice, Inbred C57BL; Neurogenesis; Neurons; Olfactory Bulb; Oxidopamine; Parkinsonian Disorders; Pramipexole; Random Allocation | 2015 |
Relative contributions of severe dopaminergic neuron ablation and dopamine depletion to cognitive impairment.
Topics: Animals; Anxiety; Benzazepines; Benzothiazoles; Brain; Cognition Disorders; Diphtheria Toxin; Discrimination Learning; Disease Models, Animal; Dopamine; Dopamine Agonists; Dopamine Plasma Membrane Transport Proteins; Dopaminergic Neurons; Gene Expression Regulation; Memory; Mice; Mice, Transgenic; Motor Activity; Pramipexole; Psychomotor Performance; Spatial Learning; Tyrosine 3-Monooxygenase | 2015 |
[Mirapex (pramipexole) in the treatment of non-motor disturbances in Parkinson's disease].
Topics: Antiparkinson Agents; Anxiety; Benzothiazoles; Depression; Dose-Response Relationship, Drug; Follow-Up Studies; Humans; Middle Aged; Parkinson Disease; Pramipexole; Receptors, Dopamine D1; Sleep Wake Disorders; Treatment Outcome | 2008 |
Delusion of Cotard's syndrome successfully treated with a dopamine agonist.
Topics: Antidepressive Agents, Second-Generation; Anxiety; Benzothiazoles; Delusions; Depressive Disorder, Major; Dopamine Agonists; Female; Follow-Up Studies; Humans; Middle Aged; Paroxetine; Pramipexole; Recurrence; Syndrome; Treatment Outcome | 2010 |
Pharmacological evaluation of the adequacy of marble burying as an animal model of compulsion and/or anxiety.
Topics: Animals; Anti-Anxiety Agents; Anxiety; Anxiety Disorders; Behavior, Animal; Benzothiazoles; Carbolines; Central Nervous System Stimulants; Compulsive Behavior; Convulsants; Dextroamphetamine; Diazepam; Disease Models, Animal; Dopamine Agonists; Dose-Response Relationship, Drug; Male; Mice; Motor Activity; Obsessive-Compulsive Disorder; Pramipexole; Reproducibility of Results | 2011 |
[Dopamine receptors agonists (mirapex) in the treatment of Parkinson's disease].
Topics: Anxiety; Benzothiazoles; Carbidopa; Delayed-Action Preparations; Depression; Dopamine Agonists; Drug Combinations; Drug Therapy, Combination; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Pramipexole; Receptors, Dopamine D1; Thiazoles; Treatment Outcome | 2006 |